Trial Profile
A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Emvododstat (Primary) ; Docetaxel
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 07 May 2019 Status changed from suspended to discontinued.
- 06 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 27 May 2010 Planned number of patients changed from 42 to 76 as reported by ClinicalTrials.gov.